TD Cowen & Evercore ISI Praise “Compelling” EDIT-401 Data as Editas Eyes 2026 Human Trials
Editas’ gene therapy EDIT-401 cut bad cholesterol ~90% in animals; analysts bullish; human trials expected in 2026.
/ 3 items
#EDIT↓
FDA’s New Fast-Track Plan for Custom Gene Editing Could Transform Rare Disease Treatments
The FDA is unveiling a faster approval pathway for custom gene-editing therapies, aiming to spark major investment and accelerate cures for rare diseases through Crispr-based innovations.
Intellia Pauses Gene Therapy Trials After Patient Develops Severe Liver Injury
Intellia Therapeutics halts MAGNITUDE trials of nex-z gene therapy after patient hospitalization with Grade 4 liver toxicity. Over 650 patients enrolled in ATTR amyloidosis studies.